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To assess gender-, pubertal-, age-related diﬀerences in change from baseline height standard deviation score (ΔHSDS), data from
5,797 growth hormone (GH) na¨ ıve pediatric patients (<18 years) with growth hormone deﬁciency (GHD), multiple pituitary
hormone deﬁciency (MPHD), Turner syndrome (TS), small for gestational age (SGA), Noonan syndrome (NS), and idiopathic
short stature (ISS) were obtained from the ANSWER (American Norditropin Studies: Web-enabled Research) Program registry.
For patients with SGA, ΔHSDS at year 1 was signiﬁcantly greater for males versus females (P = .016), but no other gender
diﬀerences were observed. For patients with GHD, ΔHSDS was greater in prepubertal than in pubertal patients. Younger patients
for both genders (<11 years for boys; <10 years for girls) showed a greater ΔHSDS (P<. 05 for GHD, MPHD, and ISS). Overall,
positive ΔHSDSs were observed in all patients, with greater growth responses in younger prepubertal children, emphasizing the
importance of starting GH treatment early.
1.Introduction
Growth hormone (GH) promotes linear growth that is
mediated, at least in part, through increased production
of insulin-like growth factor-1 (IGF-I) [1]. The pediatric
indications for recombinant human GH approved by the
United States Food and Drug Administration (FDA) include
treatment of children with growth failure due to GH deﬁ-
ciency; children with short stature associated with Noonan
syndrome (NS), Turner syndrome (TS), and Prader-Willi
syndrome (PWS); children with short stature born small
for gestational age (SGA) who have not reached normal
growthrangebyage2–4years;shortstaturewithhomeobox-
containing gene deﬁciency; children with chronic renal
insuﬃciency; children with idiopathic short stature (ISS)
who are >2.25 standard deviations (SD) below the mean
in height and who are unlikely to catch up in height [1–
4].
Treatment with GH has been shown to be highly eﬀective
for the treatment of pediatric patients with GH deﬁciency,
with increases in both short-term growth and adult height
[5–8]. Yet, the treatment outcomes are variable. Review
of results in which GH was administered to GH-deﬁcient
children <4 years of age indicated that, on average, they
achieved adult heights about 1 SD below the population
mean [5]. Another report demonstrated that GH admin-
istration to children with GH deﬁciency (GHD) results in
nearly normal adult height and normal peak bone mass,
as well as potentially decreasing the risk of cardiovascular
disease [6]. Meta-analysis of results from 10 randomized
clinical trials in which GH was administered to children with
ISS indicated that short-term height gains can range from
zero to approximately 0.7 SDS over 1 year, and that this
treatment also improved near-adult height. However, despite
these increases, patients attained heights that were relatively
short when compared with peers of normal stature [7].2 International Journal of Pediatric Endocrinology
A meta-analysis of 4 studies that included 365 girls with TS
indicated that administration of GH signiﬁcantly increased
growth velocity over 1 and 2 years. Results from one trial
that reported adult height in TS, indicated a mean height of
148cm in 61 GH-treated patients versus 141cm in 43 who
were untreated [8].
Results from a number of studies have indicated that
speciﬁc patient factors, such as age and gender, may signif-
icantly inﬂuence the response to GH therapy. Assessment of
responses to GH treatment in 111 short-stature, prepubertal,
GH-deﬁcient children indicated that the dose response to
0.025, 0.05, or 0.1mg/kg/day, for both auxological and bio-
chemical parameters, diﬀered between prepubertal females
and males. Males had a linear GH dose response, whereas
females had an apparent plateau of both linear growth
and IGF-I standard deviation score (SDS) responses at
0.05mg/kg per day [9]. Results from some registry and
modeling studies have suggested that gender may play a role
in the level of growth response to GH treatment [10, 11].
Norditropin [somatropin (rDNA origin) injection] is
indicated for the treatment of children with growth failure
due to GHD, with short stature associated with NS and TS,
and with short stature in children born SGA with no catch-
up growth by age 2–4 years. It is also indicated for treatment
of adults with either adult or childhood onset of GHD [12].
Since 2002, the ANSWER (American Norditropin Studies:
Web-enabled Research) Program has collected information
on patients receiving Norditropin. The use of Norditropin
in patients within the ANSWER Program is at the discretion
of the participating physicians and may include additional
diagnostic conditions that warrant treatment with GH. The
present study was carried out using data from the ANSWER
Programregistrytoassessgender-,pubertal-,andage-related
diﬀerences in change from baseline in height standard devi-
ation scores (HSDSs) across diﬀerent diagnostic categories
of GH-treatment-na¨ ıve pediatric patients who were treated
with Norditropin.
2.SubjectsandMethods
2.1. ANSWER Program Registry. Data for this analysis were
obtained from the ANSWER Program registry, a collection
of long-term eﬃcacy and safety information on patients
treated with Norditropin in the United States. The ANSWER
Program registry enrolls GH-treatment-na¨ ıve and -nonna¨ ıve
patients. Patient histories and physical examination data
are entered by participating physician investigators using
the ANSWER Program registry reporting form, a web-
based data entry tool. For the purpose of this analysis,
patients from the following categories were included: (1)
GHD (isolated/idiopathic), (2) multiple pituitary hormone
deﬁciency (MPHD), (3) TS, (4) SGA, (5) NS, and (6)
ISS. Only results from GH-treatment-na¨ ıve patients were
included in the analyses.
2.2. Data Collection for ANSWER Program Registry. At the
initial visit, study investigators collected baseline HSDS,
weight, pretreatment bone age, Tanner stage (according to
breast and pubic hair), maximal stimulated serum GH con-
centration, and serum IGF-I concentrations. Data collected
from follow-up clinic visits included GH dose/frequency,
height, weight, Tanner stage, and IGF-I concentration.
2.3. Evaluation Methods for Analysis. Data from pediatric
patients who were treatment na¨ ıve were collected and
analyzed at baseline, 1 year, and 2 years. Data at each time
point were collected within a 3-month window. HSDS (z
score) was calculated according to the standard formulas
provided by the Center for Disease Control and Prevention
[13]. The following rules were used to exclude patients from
analysis: baseline age <0o r>18 years, baseline HSDS less
than −5 or greater than +2, and baseline height <35 or
>200cm. Potential subjects were excluded from the analysis
if key variables had baseline or subsequent values that were
deemed physically or chronologically impossible (3.77% of
potential subjects were excluded according to these criteria).
Data analyzed included HSDS change from baseline
(ΔHSDS) at 1 year and 2 years of GH treatment, ΔHSDS
by gender and pubertal status (deﬁned by Tanner stage
classiﬁcation [14]) or age at start of treatment, and a
least-squares means analysis of ΔHSDS by gender. Pubertal
status was assigned by the physician and categorized as
follows: prepubertal patients (Tanner stage I throughout),
prepubertal/pubertal patients (transitioned from Tanner
stage I to Tanner stage II or more), and pubertal patients
(Tanner stage II or more at baseline). For analyses of age at
start of treatment, age ranges were deﬁned to be <11 or ≥11
years of age for male patients, and <10 or ≥10 years of age
for female patients.
Statistical comparisons of ΔHSDS between age groups
stratiﬁed by gender and diﬀerent diagnostic categories were
conducted using the two-sample t-test. No adjustment
for multiplicity of testing was done. The diﬀerences were
considered statistically signiﬁcant if the corresponding P
values ≤.05.
3. Results
The ANSWER Program registry (as of November 2009) con-
tained information for 5,797 GH-treatment-na¨ ıve patients
from the following categories: GHD (isolated/idiopathic),
MPHD, TS, SGA, NS, and ISS.
3.1. Patient Demographics. Baseline demographic charac-
teristics for the subjects are summarized in Table 1.T h e
study included 3,870 patients with GHD, 355 with MPHD,
382 with TS, 360 with SGA, 79 with NS, and 751 with
ISS. Information summarized in Table 1 indicates that the
subjects with MPHD, SGA, and TS were generally younger
at baseline compared with those in the other diagnostic
categories. The lowest mean peak GH levels were observed
in patients with GHD (isolated/idiopathic) and MPHD, 5.3
and 3.1ng/mL, respectively. On average, older baseline age
was observed for patients with GHD, NS, and ISS. Baseline
GH dose (in mg/kg) information for the diﬀerent diagnostic
categories demonstrates slightly higher doses for ISS, TS,International Journal of Pediatric Endocrinology 3
Table 1: Baseline demographics.
GHD MPHD TS SGA NS ISS
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Gender, M/F 2,918/952 220/135 0/382 224/136 58/21 528/223
Age, yr 3,870 10.8 ± 3.54 355 7.5 ± 5.45 382 8.6 ± 4.03 360 8.4 ± 3.74 79 9.6 ± 3.76 751 11.2 ± 3.06
HSDS 3,870 −2.2 ± 0.89 355 −1.9 ± 1.39 382 −2.6 ± 0.9 360 −2.6 ± 0.89 79 −2.7 ± 0.70 751 −2.3 ± 0.75
IGF-I SDS 3,360 −2.5 ± 1.42 184 −3.2 ± 1.67 220 −1.9 ± 1.22 258 −2.4 ± 1.68 65 −2.8 ± 1.27 701 −2.2 ± 1.45
Bone age, yrs 3,369 9.3 ± 3.41 186 8.5 ± 4.5 256 8.0 ± 3.46 296 7.3 ± 3.68 66 8.0 ± 3.75 667 9.6 ± 3.31
Baseline GH
dose, mg/kg/day
3,514 0.047 (0.0121) 319 0.039 (0.0123) 357 0.051 (0.0098) 325 0.052 (0.0137) 72 0.047 (0.0106) 644 0.050 (0.0127)
Peak GH,
ng/mL
3,326 5.3 ± 2.77 202 3.1 ± 3.04 16 18.2 ± 31.54 138 14.4 ± 13.69 32 10.8 ± 9.13 542 17.1 ± 20.09
Baseline HSDS
(males)
2918 −2.1 ± 0.85 220 −1.9 ± 1.36 — — 224 −2.5 ± 0.83 58 −2.6 ± 0.69 528 −2.2 ± 0.71
Baseline HSDS
(female)
952 −2.4 ± 0.97 135 −1.9 ± 1.44 382 −2.6 ± 0.90 136 −2.7 ± 0.97 21 −2.9 ± 0.69 223 −2.4 ± 0.82
GHD: idiopathic growth hormone deﬁciency; MPHD: multiple pituitary hormone deﬁciency; TS: Turner syndrome; SGA: short for gestational age; NS:
Noonan syndrome; ISS: idiopathic short stature.
SGA, and GHD compared to MPHD patients, which may be
as expected, since they are the most GH deﬁcient.
Although the dose for patients with NS may be slightly
lower than expected, this may be due to the fact that there
are fewer patients in this category. Baseline HSDS for male
and female subjects in each diagnostic group are also sum-
marized in Table 1. Overall, mean HSDS values for diﬀerent
diagnostic groups varied from −1.9 to −2.6 for males and
−1.9 to −2.9 for females. Generally, greater baseline HSDS
were observed with male patients and signiﬁcant diﬀerences
were observed between male and female baseline HSDS for
patients with GHD, ISS, and NS (P<. 0001, P = .0121,
P = .0459, resp.).
3.2. Eﬀects of GH Treatment on HSDS. Eﬀects of GH
treatment on HSDS are summarized in Figures 1 and 2,
respectively, for each diagnosis category and for male and
female subjects in each of these groups. The overall eﬀects of
GH treatment on absolute values for HSDS across diagnostic
categories are shown in Figure 1(a). Patients in all treatment
groups had positive changes in HSDS over 2 years of follow-
up. ΔHSDS at 1 year ranged from 0.4 for ISS, TS, and
NS to 0.7 for MPHD. At the end of 2 years, the ΔHSDS
ranged from 0.6 for NS to 1.0 for GHD, MPHD, and SGA.
Corresponding average GH doses at baseline and end of year
1 and year 2 are depicted in Figure 1(b). For all diagnostic
categories, dose generally remained stable over two years
except for NS at end of year 1 where a mild increase in dose is
apparent. Not surprisingly, subjects with MPHD received the
lowest GH dose over two years, consistent with the greater
degree of GHD as reﬂected in their very low serum IGF-
I and peak GH concentrations at baseline (Table 1). The
resultsinFigure 2showthattreatmentresultedinsubstantial
changes in HSDS in both the male and female subjects over
2 years of treatment. Analysis of results for all diagnostic
categories except SGA indicated no signiﬁcant diﬀerences
between results for male and female subjects over 2 years of
treatment.ForsubjectswithSGA,theΔHSDSintheﬁrstyear
of treatment was signiﬁcantly greater for male versus female
subjects (0.69 versus 0.53, P = .016).
ΔHSDS for prepubertal and pubertal patients with
GHD was analyzed according to whether they remained
prepubertal, became pubertal, or were pubertal during the
entire 2-year treatment interval (Table 2). ΔHSDS (mean ±
SD) in both years of treatment was observed for subjects
who were prepubertal (0.64 ± 0.53 year 1; 1.15 ± 0.73 year
2), pubertal (0.48 ± 0.36 year 1; 0.95 ± 0.56 year 2), or who
transitioned from prepubertal to pubertal during the 2-year
study period (0.50 ± 0.41 year 1; 0.94 ±0.53 year 2).
Table 3 shows ΔHSDS for male and female subjects who
were stratiﬁed by age at treatment start (<11 or ≥11 for
males, <10 or ≥1 0f o rf e m a l e s ) .Y o u n g e rm a l ea n df e m a l e
subjectsfromeachdiagnosticgroupgenerallyshowedgreater
ΔHSDS. Except for Noonan syndrome and SGA, results
for male and female subjects in each diagnostic category
indicated signiﬁcantly greater ΔHSDS at both years 1 and
2 for those with initiation of treatment at the younger age.
Except for male patients in year 1, there was no statistically
signiﬁcant diﬀerence observed between younger and older
Noonan syndrome patients. A similar lack of diﬀerence
between age groups was noted for female SGA subjects.
4. Discussion
Results from 2 years of GH treatment of subjects in the
ANSWER Program registry demonstrated increased HSDS
from baseline in a large cohort of male and female subjects
with ISS, GHD, MPHD, SGA, TS, and NS. Study results
did not demonstrate any substantial gender diﬀerences for
patients with ISS, GHD, MPHD, NS, or SGA. The only
diﬀerence between male and female subjects that achieved
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Figure 1: (a) HSDS at baseline, year 1, and year 2 following
treatment with GH for patients with GHD, MPHD, TS, SGA, NS,
or ISS. (b) GH dose at baseline, year 1, and year 2 for patients
with GHD, MPHD, TS, SGA, NS, or ISS. GHD: isolated/idiopathic
growth hormone deﬁciency; MPHD: multiple pituitary hormone
deﬁciency;TS:Turnersyndrome;SGA:shortforgestationalage;NS:
Noonan syndrome; ISS: idiopathic short stature.
SGA (male > female), which may or may not be clinically
signiﬁcant.
The general lack of eﬀect of gender on response to GH
treatment observed in this registry analysis is consistent
with results from a large number of studies that evaluated
eﬀects of gender on response to GH. Analysis of results
from the Pﬁzer Kabi International Growth Study (KIGS)
database indicated no signiﬁcant gender-related diﬀerences
in eﬀects of GH on growth velocity or HSDS over 2 or 3
years of treatment [15]. Analysis of the short- and long-term
eﬀects of GH treatment on growth in prepubertal children
with chronic renal failure also indicated no signiﬁcant eﬀects
of gender [16]. Evaluation of predictors of response to
treatmentwithGHforupto7yearsin8,018patientswithISS
indicated no signiﬁcant eﬀect of gender on ﬁrst-year growth
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Figure 2: HSDS change from baseline by gender following
treatment with GH for patients with GHD, MPHD, TS, SGA, NS,
and ISS measured over 2 years. ∗male > female, P = .016. GHD:
isolated/idiopathic growth hormone deﬁciency; MPHD: multiple
pituitary hormone deﬁciency; TS: Turner syndrome; SGA: short
for gestational age; NS: Noonan syndrome; ISS: idiopathic short
stature.
Table 2: HSDS change from baseline by pubertal status for patients
with GHD.
Year 1 Year 2
N Mean ± SD N Mean ± SD
Prepubertala 1128 0.64 ± 0.53 610 1.15 ± 0.73
Prepubertal/Pubertal 572 0.50 ± 0.41 638 0.94 ± 0.53
Pubertal 772 0.48 ± 0.36 474 0.95 ± 0.56
aPubertal status assigned by the physician; prepubertal were Tanner I
throughout, prepubertal/pubertal patients transitioned into Tanner II or
more, pubertal patients were Tanner II or more at baseline.
results from a French registry that included 2,852 patients
with idiopathic GHD indicated that female gender was a
signiﬁcant positive predictor of adult height gain with GH
treatment [10].
Analyses did show that ΔHSDS was signiﬁcantly greater
for subjects who started GH treatment at a younger age.
While results from the ANSWER Program registry suggest
that many patients start GH treatment later than desired,
multiple studies suggest better growth outcomes with earlier
intervention. For example, the Consensus Statement on
the Diagnosis and Treatment of Children with Idiopathic
Short Stature indicates that the optimal age for initiation
of treatment is 5 years of age to early puberty [18]. The
mean age at initiation of therapy for children with ISS in
this analysis was 11.2 years and near the upper end of
the recommended age range. Similarly, the International
Small for Gestational Age Advisory Board Consensus Devel-
opment Conference Statement indicated that patients who
begin therapy at 9-10 years of age will experience lower
growth velocity than those who start treatment earlier [19].International Journal of Pediatric Endocrinology 5
Table 3: HSDS change from baseline stratiﬁed by age at treatment start and gender.
Male Female
<11 years ≥11 years P-value <10 years ≥10 years P-value
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
GHD Year 1 759 0.75 ± 0.52 1,169 0.41 ± 0.36 <.0001 272 0.78 ± 0.54 324 0.48 ± 0.40 <.0001
Year 2 555 1.20 ± 0.68 780 0.85 ± 0.54 <.0001 206 1.25 ± 0.65 214 0.91 ± 0.58 <.0001
MPHD Year 1 96 0.85 ± 1.07 45 0.27 ± 0.40 <.0001 46 0.86 ± 0.82 35 0.29 ± 0.45 .0002
Year 2 81 1.26 ± 1.07 24 0.54 ± 0.82 .0033 27 1.33 ± 1.22 23 0.60 ± 0.70 .0114
TS Year 1 — — — — — 145 0.56 ± 0.40 101 0.25 ± 0.36 <.0001
Year 2 — — — — — 107 0.84 ± 0.54 66 0.63 ± 0.56 .0168
SGA Year 1 101 0.82 ± 0.53 30 0.27 ± 0.28 <.0001 52 0.58 ± 0.55 25 0.41 ± 0.35 .0931
Year 2 63 1.23 ± 0.60 14 0.59 ± 0.51 .0005 29 1.00 ± 0.74 13 0.87 ± 0.51 .5670
NS Year 1 18 0.53 ± 0.41 12 0.16 ± 0.38 .0212 6 0.31 ± 0.45 5 0.26 ± 0.47 .8565
Year 2 10 0.83 ± 0.84 5 0.25 ± 0.45 .1763 1 0.23 ± — 1 0.10 ± ——
ISS Year 1 115 0.60 ± 0.44 208 0.38 ± 0.29 <.0001 47 0.71 ± 0.37 92 0.35 ± 0.38 <.0001
Year 2 83 0.96 ± 0.63 110 0.79 ± 0.51 .0400 33 1.25 ± 0.61 48 0.73 ± 0.62 .0004
P values are for comparisons between age groups for each year
GHD: isolated/idiopathic growth hormone deﬁciency; MPHD: multiple pituitary hormone deﬁciency; TS: Turner syndrome; SGA: short for gestational age;
NS: Noonan syndrome; ISS: idiopathic short stature.
The mean age at initiation of treatment for subjects with
SGA included in this analysis was 8.4 years. Guidelines for
the treatment of childhood GHD do not provide speciﬁc
guidance on the optimal time for initiation of therapy
[1, 2]. However, earlier recommendations from the Growth
Hormone Research Society indicate that treatment should
be initiated as soon as the diagnosis is made [20]. Current
guidelines do not provide a speciﬁc recommendation for
timing of treatment initiation in patients with TS [1, 21],
but one review suggested treatment initiation at 4–6 years
of age [22]. The Turner Syndrome Study Consensus Group
suggested that treatment with GH should be considered as
soon as growth failure is demonstrated and potential risks
andbeneﬁtsoftreatmenthavebeendiscussedwiththefamily
[21]. This recommendation is consistent with clinical trial
results indicating that initiation of GH as early as 9 months
of age in patients with TS is safe and results in signiﬁcant
improvements in length/height SDS [23]. Results from a
study of 1,478 females with TS in Japan indicated that the
percent of patients with initiation of treatment at <5y e a r s
oldwas5.11%fortheperiodof1991to1994butincreasedto
16.85% for the period from 2000 to 2004, with pretreatment
mean HSDS scores of −3.41 ± 0.87 and −3.17 ± 0.79,
respectively (P<. 0001). Mean ages at initiation of treatment
for these 2 periods were 10.95 and 8.78 years, respectively
[24].
Baseline data for subjects included in this analysis of
the ANSWER Program registry also indicated lower mean
baseline HSDS scores for female subjects compared with
male subjects across all diagnostic categories, and these
diﬀerences were signiﬁcant for patients with GHD, ISS, and
NS.Thismaybeduetoareferralbiaswithearlierrecognition
ofshortstatureandtreatmentinmaleversusfemalepatients.
This bias in treatment has been documented in a recent
analysis of results from 1,485 Australian children included in
the OZGROW database [25]. Results from the United States
also indicate that there is almost 2:1 male to female ratio for
patients referred for GH treatment [26].
Overall, the ΔHSDS observed in this study for year 1,
rangingfrom0.4–0.7,andyear2,rangingfrom0.6–1.0across
all diagnostic categories, is consistent with ﬁndings from
other clinical trials of GH treatment. Results from a meta-
analysis of 10 trials with 1-year follow-up data indicated
am e a nΔHSDS of 0.43 for patients with ISS [27]. Within
the meta-analysis study, 4 studies had 2-year follow-up data
taken from a total of 128 patients, which indicated a ΔHSDS
of about 0.7 [27]. In a registry study of 704 patients with TS,
a 1-year gain in HSDS of 0.6 was observed [28]. Data from
another registry of patients with isolated idiopathic GHD
found a gain in HSDS of 1.0 following 3.6 years of treatment
with GH but where the majority of the height was gained
during the ﬁrst 2 years [10].
Theimportanceoftimingoftreatmentinitiationdemon-
stratedbythisanalysisisalsosupportedbyresultsfromother
studies of pediatric patients treated with GH. A report by
Ranke et. al. validating a mathematical model for predicting
the response of pediatric patients with idiopathic GHD to
treatment with GH reiterated that chronologic age at start
of treatment and maximum baseline GH response were the
top two (out of six) parameters predicting ﬁrst year height
velocity. Also, second and third year height velocity were
primarily predicted by the growth velocity in the previous
year [29]. Although the purpose of the current analysis was
not to develop a prediction model, our results are consistent
with both younger age at treatment start and baseline peak
GH inversely correlating with ﬁrst year growth response,
particularly in GHD and MPHD subjects. In a recent follow-
up analysis for predicting two-year growth responses to GH6 International Journal of Pediatric Endocrinology
therapy in prepubertal children with either severe GHD, less
severe GHD, TS, or SGA, Ranke and Lindberg developed
criteria deﬁning an adequate ﬁrst year ΔHSDS [30]. For
patients with severe GHD (peak GH < 5µg/L), an adequate
ﬁrst year response was deﬁned as ΔHSDS ≥ 0.4, whereas
for less severe GHD (peak GH 5–10µg/L), TS, and SGA,
a ΔHSDS ≥ 0.3 in the ﬁrst year indicated an adequate
response.ThegrowthresponsestoGHinthecurrentanalysis
of subjects from the ANSWER Program registry would
meet these criteria since the ﬁrst year mean ΔHSDS ranged
between 0.4 and 0.7 for all diagnostic categories. However,
when stratiﬁed by age, this did not hold up for all older
subjects (males ≥ 11 and females ≥ 10) in some categories
(MPHD, TS, SGA, NS), emphasizing the importance of
younger age at treatment start. In this regard, it is important
to note that subjects included in our analysis ranged between
0.5 and 18 years of age, whereas the age range in the Ranke
analysis model was 1 to12 years [30].
According to a registry study that included information
from 3,007 patients with idiopathic GH deﬁciency, 1378
with TS, and 65 with NS, the duration of prepubertal, GH
treatment correlated signiﬁcantly with achievement of near-
normal adult height [31]. Other registry studies have also
suggested that prepubertal initiation of treatment results in
greater improvements in HSDS. According to results from
the National Registry of Growth Hormone Treatment in the
Netherlands that included 342 patients with GHD, initiation
of treatment before puberty resulted in a ΔHSDS of 0.71
versus 0.58 for those who started treatment after pubertal
onset [32]. The French registry study of 2,852 patients
with idiopathic GHD also demonstrated greater adult height
gain with prepubertal initiation of GH treatment [10]. One
exception to this general trend toward greater beneﬁt of GH
treatment in prepubertal versus pubertal patients involves
results from a study of 83 patients with GHD who were
treated for 2 to 7 years, that indicated no signiﬁcant eﬀect
with respect to adult height achieved [33].
In conclusion, in this analysis of data from the ANSWER
Program registry, GH treatment resulted in increased HSDS
in subjects with idiopathic/isolated GHD, MPHD, TS, NS,
and ISS. No consistent gender eﬀect was observed in ΔHSDS
after 2 years of therapy. However, on average, initiation of
treatment at a younger age or before the start of puberty
(GHD patients) resulted in greater ΔHSDS. Due to the
greater growth response, which was apparent in younger,
prepubertal children, the importance of starting growth
hormone treatment at a younger age should continue to be
emphasized.
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